SINO LION VENTURES (INDP) discloses 38.9M-share Indaptus stake via preferred conversion

Rhea-AI Filing Summary

SINO LION VENTURES Ltd has become a major shareholder of Indaptus Therapeutics, Inc. by converting preferred stock into common shares. On March 19, 2026, it agreed to acquire 259,300 shares of Series AAA Convertible Non-Redeemable Preferred Stock from David Elliot Lazar. Each preferred share is convertible into 150 shares of common stock. After the transaction closed on March 23, 2026, SINO LION VENTURES Ltd submitted a notice of conversion for all of its Series AAA Preferred Stock, resulting in the issuance of 38,895,000 shares of common stock, which it now holds directly as reported on this initial Form 3. A footnote states these securities may also be deemed beneficially owned by Chenhao Xu, who disclaims beneficial ownership except for any pecuniary interest.

Insights

Equity ownership analyst

Large new 10%+ holder discloses a 38.9M-share position via conversion.

SINO LION VENTURES Ltd reports initial beneficial ownership in Indaptus Therapeutics through a structured preferred-to-common transaction. It purchased 259,300 shares of Series AAA Convertible Non-Redeemable Preferred Stock, each convertible into 150 common shares, then promptly converted the entire position.

The full conversion on March 23, 2026 yielded 38,895,000 common shares, creating a significant single holder position. This filing is primarily informational, showing who controls this block rather than indicating ongoing trading activity or pricing terms.

A footnote notes the securities may also be deemed beneficially owned by Chenhao Xu, who disclaims beneficial ownership beyond any pecuniary interest. Subsequent company disclosures may further clarify governance, lock-up terms, or any related agreements tied to this ownership change.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SINO LION VENTURES Ltd

Role 10% Owner

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 38,895,000 shares (Direct)

Footnotes (1)

1. On March 19, 2026, Sino Lion Ventures Limited (the "Reporting Person"), the other purchasers named therein and David Elliot Lazar (the "Seller") entered into a securities purchase agreement pursuant to which the Reporting Person acquired an aggregate of 259,300 shares of the Issuer's Series AAA Convertible Non-Redeemable Preferred Stock (the "Series AAA Preferred Stock"). Each share of Series AAA Preferred Stock is convertible into 150 shares of the Issuer's common stock, $0.01 par value per share (the "Common Stock"). Following the closing of such transaction on March 23, 2026, the Reporting Person submitted a notice of conversion with respect to all shares of Series AAA Preferred Stock held by the Reporting Person, resulting in the issuance of an aggregate of 38,895,000 shares of Common Stock. The reported securities may also be deemed to be beneficially owned by Chenhao Xu, whom disclaims beneficial ownership of these shares except to the extent of his pecuniary interest in such shares, if any.

Key Figures

Common shares owned: 38,895,000 shares Series AAA Preferred shares acquired: 259,300 shares Conversion ratio: 150 shares of common per preferred share +2 more

5 metrics

Common shares owned 38,895,000 shares Total common stock held following conversion as of March 23, 2026

Series AAA Preferred shares acquired 259,300 shares Series AAA Convertible Non-Redeemable Preferred Stock purchased on March 19, 2026

Conversion ratio 150 shares of common per preferred share Each Series AAA Preferred share converts into 150 common shares

Ownership type Ten percent owner SINO LION VENTURES Ltd identified as 10% owner of Indaptus Therapeutics

Form type Form 3 Initial statement of beneficial ownership of securities

Key Terms

Series AAA Convertible Non-Redeemable Preferred Stock, beneficially owned, pecuniary interest, notice of conversion

4 terms

Series AAA Convertible Non-Redeemable Preferred Stock financial

"acquired an aggregate of 259,300 shares of the Issuer's Series AAA Convertible Non-Redeemable Preferred Stock"

beneficially owned financial

"The reported securities may also be deemed to be beneficially owned by Chenhao Xu"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

pecuniary interest financial

"disclaims beneficial ownership of these shares except to the extent of his pecuniary interest in such shares"

notice of conversion financial

"the Reporting Person submitted a notice of conversion with respect to all shares of Series AAA Preferred Stock"

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

SINO LION VENTURES Ltd

(Last) (First) (Middle)

C/O INDAPTUS THERAPEUTICS, INC

3 COLUMBUS CIRCLE, 15TH FLOOR

(Street)

NEW YORK NEW YORK 10019

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/23/2026

3. Issuer Name and Ticker or Trading Symbol
Indaptus Therapeutics, Inc. [ INDP ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	38,895,000(1)(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On March 19, 2026, Sino Lion Ventures Limited (the "Reporting Person"), the other purchasers named therein and David Elliot Lazar (the "Seller") entered into a securities purchase agreement pursuant to which the Reporting Person acquired an aggregate of 259,300 shares of the Issuer's Series AAA Convertible Non-Redeemable Preferred Stock (the "Series AAA Preferred Stock"). Each share of Series AAA Preferred Stock is convertible into 150 shares of the Issuer's common stock, $0.01 par value per share (the "Common Stock"). Following the closing of such transaction on March 23, 2026, the Reporting Person submitted a notice of conversion with respect to all shares of Series AAA Preferred Stock held by the Reporting Person, resulting in the issuance of an aggregate of 38,895,000 shares of Common Stock.

2. The reported securities may also be deemed to be beneficially owned by Chenhao Xu, whom disclaims beneficial ownership of these shares except to the extent of his pecuniary interest in such shares, if any.

	/s/ Chenhao Xu	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does SINO LION VENTURES Ltd report in its Form 3 for Indaptus Therapeutics (INDP)?

SINO LION VENTURES Ltd reports initial beneficial ownership in Indaptus Therapeutics common stock. It holds 38,895,000 common shares obtained by fully converting a preferred stock position, making it a large shareholder and a ten percent owner of the company.

How did SINO LION VENTURES Ltd obtain 38,895,000 Indaptus Therapeutics (INDP) common shares?

SINO LION VENTURES Ltd acquired 259,300 shares of Series AAA Convertible Non-Redeemable Preferred Stock, then converted all of them. Each preferred share converts into 150 common shares, resulting in the issuance of 38,895,000 Indaptus Therapeutics common shares to the reporting person.

What are the key terms of the Series AAA Preferred Stock reported for Indaptus Therapeutics (INDP)?

The Series AAA Convertible Non-Redeemable Preferred Stock is convertible into common stock at a fixed ratio. Each share of Series AAA Preferred Stock converts into 150 shares of Indaptus Therapeutics common stock, enabling large common share positions when blocks of preferred shares are fully converted.

When did SINO LION VENTURES Ltd convert its Indaptus Therapeutics preferred stock into common shares?

The conversion occurred after the transaction closed on March 23, 2026. Following the closing, SINO LION VENTURES Ltd submitted a notice of conversion for all of its Series AAA Preferred Stock, leading to the issuance of 38,895,000 Indaptus Therapeutics common shares.

Who else may be deemed to beneficially own the Indaptus Therapeutics (INDP) shares reported by SINO LION VENTURES Ltd?

The filing states the reported securities may also be deemed beneficially owned by Chenhao Xu. He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest in them, if any, as described in the footnote.